Area of Science:

• Oncology
• Health Economics
• Health Policy

Background:

• The introduction of novel immunotherapy anticancer drugs represents a significant advancement in cancer treatment.
• These drugs often receive accelerated approval and orphan drug status, contributing to high market prices.
• Current pricing strategies and regulatory pathways are leading to unsustainable healthcare spending.

Purpose of the Study:

• To analyze the economic impact of new immunotherapy drugs on healthcare spending.
• To evaluate the current regulatory model for anticancer drugs and propose improvements.
• To discuss the implications for oncologists, patients, and policymakers regarding drug pricing and access.

Main Methods:

• Review of current pricing and approval processes for immunotherapy drugs.
• Analysis of healthcare spending trends related to oncology treatments.
• Discussion of potential regulatory and market-based solutions, including Health Technology Assessment (HTA).

Main Results:

• High reference prices, accelerated approvals, and orphan drug designations contribute to escalating costs.
• The current system risks becoming unsustainable due to unrealistic drug prices.
• Potential solutions like HTA and market deregulation face significant challenges and resistance.

Conclusions:

• The current regulatory framework for anticancer drugs requires substantial revision to ensure sustainability.
• Implementing Health Technology Assessment (HTA) could introduce cost-effectiveness evaluations, impacting drug prices.
• Oncologists and patient associations must engage in price discussions to navigate treatment rationing and financial toxicity.